Merck Down to its Last Cubicin Patent

Merck & Co. company Cubist Pharmaceuticals has only one patent left covering its Cubicin antibiotic. Hospira, which is planning a to release a generic version of the drug, had previously challenged five Cubist patents, rendering four of them invalid and only leaving the oldest, which is set to expire in June 2016, in tact.